Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

immunotherapy

immunotherapy is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 37
News articles 0
Drug details — immunotherapy
Class
—
Route
—
Patents
20
Programs
37
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

immunotherapy is an FDA-listed pharmaceutical active ingredient.

Key facts

INN immunotherapy

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Adjuvant immunotherapy Phase 3 · Chinese Academy of · Nasopharyngeal Carcinoma
  2. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC) Phase 3 · Lisata Therapeutics · Stage IV Melanoma
  3. DIDaC/ NVALT35 Phase 3 · Disc Medicine · Patients with advanced, metastatic NSCLC that have not progr
  4. Dendritic cell immunotherapy Phase 3 · NORTHWEST BIOTHERAPEUTICS · Glioblastoma Multiforme
  5. Dendritic cell immunotherapy Phase 3 · NORTHWEST BIOTHERAPEUTICS · Prostate Cancer
  6. UC-IMM-2101 Phase 3 · Ningbo Cancer Hospital · Only patients with oncologic locally advanced or metastatic
  7. Visilizumab Phase 3 · First People's Hospital · Immunotherapy
  8. adoptive immunotherapy Phase 3 · Chinese PLA General · Hepatocellular Carcinoma

Related patents

Browse patents

  1. US 12414983

    CD200AR ligands for cancer immunotherapy

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12384830

    Compositions and methods for improving immunotherapy

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12338459

    DNA-chimeric antigen receptor T cells for immunotherapy

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12329816

    Immunotherapy with metabolic enzyme expression

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12311030

    Antibody-sting agonist conjugates and their use in immunotherapy

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12303551

    Cellular immunotherapy compositions and uses thereof

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12297509

    Biomarkers for predicting tumor response to and toxicity of immunotherapy

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12230364

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12226434

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12230378

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12228582

    Method and apparatus for testing near infrared-photoimmunotherapy treatment

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12230379

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12194061

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12186428

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12178787

    T cell receptors for immunotherapy

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12170134

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12159700

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is immunotherapy?

immunotherapy is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.